GENTIAE Clinical Research Selects eResearchTechnologys eResearch Network Application Suite: eRT Platform to Provide Technology Foundation for Cardiovascular CRO

GENTIAE is the first Clinical Research Organization that will deploy eResearch Technology's eResNet Accelerator program. eRT's eResearch Network is a clinical research solution is a hosted application that enables CRO's, pharmaceutical, biotechnology and medical device company's to connec their organizations's sites and sponsors (of clinical studies) which helps streamline the clinical trials process.

PHILADELPHIA, PA-- eResearchTechnology, Inc. (eRT) (NASDAQ: ERES), a leading e-research technology and services provider, today announced that GENTIAE Clinical Research has selected eRTs eResearch Network solution to provide an end-to-end platform for clinical research, including electronic data capture (EDC).

GENTIAE Clinical Research, based in San Francisco, is the for-profit subsidiary of the Ischemia Research & Education Foundation (the Foundation"). More than 60 professional researchers staff the recently established CRO, including 24 M.D.s, Ph.D.s, and R.N.s. Areas of expertise include clinical trial design and project management, biostatistics and data management, and cardiovascular core laboratory services. GENTIAE draws on the domain expertise of the Foundation, which was founded in 1987 to conduct studies addressing the prevention and treatment of cardiovascular disease. To date, employees of the Foundation and the affiliated members of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group have published more than 125 articles in such peer-reviewed medical journals as the Journal of the American Medical Association, Circulation, and the New England Journal of Medicine.

We are delighted to partner with GENTIAE in establishing an electronic network among its affiliated sites around the world to fulfill its mission of providing world class clinical research for the pharmaceutical, biotechnology, and medical device industries," said Joseph Esposito, President and CEO of eRT. GENTIAE is the first CRO that will leverage eRTs recently launched eResNet Accelerator program, which delivers eRT's eResearch Network clinical research solution as a monthly service that includes application hosting and comprehensive professional services that together deliver rapid time to benefit."

eRTs innovative solution will ensure that GENTIAE has the technology platform required to optimize our enterprise processes and connect our organization to its sites and sponsors," said Michael Kokesh, GENTIAEs President and CEO. Through our affiliation with the McSPI Research Group, GENTIAE is able to conduct large-scale, multi-center studies utilizing the expertise of highly motivated and experienced physician/researchers at more than 150 research centers in 26 countries around the world. With the eResNet end-to-end clinical research suite we will be able to maintain mission-critical communications with our research sites to obtain high quality data throughout the clinical trial. With the eRT technology platform we will be able to scale up to handle the growing needs of our clients and sponsors of clinical trials."

GENTIAE is a San Francisco-based contract research organization dedicated to performing quality medical and clinical research for the pharmaceutical, biotechnology, and medical device industries. GENTIAEs distinctive market advantage is its access to the Foundations comprehensive and proprietary clinical databases, containing information on more than 26,000 cardiac surgery patients and 6,000 non-cardiac patients. With access to these proprietary databases, GENTIAE is able to support critical study design and protocol development decisions leading to an accelerated clinical development program.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com), is a business-to-business provider of integrated software applications and technology consulting services to the pharmaceutical, biotechnology and medical device industries. The Company offers Internet and other technology-based solutions designed to streamline the clinical trials process by enabling its customers to automate many parts of a clinical trial. The Company is also a market leader in providing centralized core-diagnostic electrocardiographic services on a global basis.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Forms 10-K and 10-Q filed with the Securities Exchange Commission (SEC).
                         ###